This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeuroMetrix Partners With Handok Pharmaceuticals For NC-stat DPNCheck Distribution In The Republic Of Korea

NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, announced that it has entered an agreement with Handok Pharmaceuticals, Inc. Under terms of the agreement, Handok will be the exclusive distributor for NC-stat® DPNCheck™ in the Republic of Korea. NC-stat DPNCheck is a rapid, accurate and quantitative point-of-care test for diabetic neuropathy. The product is used to detect neuropathy at an early stage and to guide treatment. Diabetic peripheral neuropathy (DPN) is the most common complication of diabetes, affecting over half of people with diabetes. DPN causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations.

The Korea market is characterized by high prevalence of people with diabetes. The Korea National Health and Nutrition Examination Survey (KNHANES), a nationwide survey examining the general health and nutrition status of the Korean people, reported in 2008 that the prevalence of diabetes in the Korea population was estimated at 10.9% representing about 2.6 million people. While the overall prevalence had not changed significantly during the seven year study period, physician diagnosis and treatment rates had significantly improved. Handok Pharmaceuticals has been a leader in supporting physicians in this field and considers diabetes to be a core business focus. It offers a range of diabetes products including systems for hemoglobin A1c testing, blood glucose meters, and pharmacological products for pain associated with nerve disease. Handok distributes its products through direct sales representatives in its hospital and physician clinic sales teams. It also works with independent distributors in Korea. It intends to utilize both direct and indirect sales channels in promoting NC-stat DPNCheck.

"As a company that values innovation in health care, we are pleased to have the opportunity to bring the diagnostic capabilities NC-stat DPNCheck to the Korea market,” stated Young-jin Kim, Handok’s CEO. “It broadens the range of products we offer to Koreans with diabetes while leveraging our established sales channels. We look forward to a long relationship with NeuroMetrix.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs